Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia

NCT00588731 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT00588731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00588731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2009
Completion date
December 31, 2013
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia